OBJECTIVES: We sought to evaluate the cardiac and renal effects of an N-acetylcysteine (NAC)-enhanced intracoronary radiographic contrast agent. BACKGROUND: Recent studies suggest that high-dose NAC provides better protection from contrast-induced nephropathy, and the antioxidant properties of NAC may also provide cardiac protection. The use of angiographic contrast agents as a drug delivery vehicle for cardiorenal protection effects has not been investigated. METHODS: In a pig model of prolonged cardiac ischemia-reperfusion, NAC-enhanced contrast medium was tested and compared with iopamidol contrast only. Myocardium and renal function were assessed after 24 h. RESULTS: There was no significant difference in the area-at-risk for myocardial infarction (MI) between contrast only and NAC-enhanced contrast medium. In contrast, MI size was about 40% smaller in NAC-enhanced contrast medium-treated animals. These findings were associated with a significant difference in MI morphology. MIs in the NAC-enhanced contrast medium group had a mottled appearance, whereas in the contrast only group they were homogeneous and had a discrete border zone. These differences could explain a higher incidence of periprocedural ventricular arrhythmias in the NAC-enhanced contrast medium group. Histopathological analysis of the myocardium revealed a reduction in programmed cell death by NAC-enhanced contrast medium that may explain the increase in ischemia tolerance. Last, NAC-enhanced contrast medium administration blunted the rise in serum creatinine levels by about 60% and protected from renotubular apotosis. CONCLUSIONS: NAC-enhanced contrast medium reduces MI size and protects renal function in a pig model of ischemia and reperfusion.
OBJECTIVES: We sought to evaluate the cardiac and renal effects of an N-acetylcysteine (NAC)-enhanced intracoronary radiographic contrast agent. BACKGROUND: Recent studies suggest that high-dose NAC provides better protection from contrast-induced nephropathy, and the antioxidant properties of NAC may also provide cardiac protection. The use of angiographic contrast agents as a drug delivery vehicle for cardiorenal protection effects has not been investigated. METHODS: In a pig model of prolonged cardiac ischemia-reperfusion, NAC-enhanced contrast medium was tested and compared with iopamidol contrast only. Myocardium and renal function were assessed after 24 h. RESULTS: There was no significant difference in the area-at-risk for myocardial infarction (MI) between contrast only and NAC-enhanced contrast medium. In contrast, MI size was about 40% smaller in NAC-enhanced contrast medium-treated animals. These findings were associated with a significant difference in MI morphology. MIs in the NAC-enhanced contrast medium group had a mottled appearance, whereas in the contrast only group they were homogeneous and had a discrete border zone. These differences could explain a higher incidence of periprocedural ventricular arrhythmias in the NAC-enhanced contrast medium group. Histopathological analysis of the myocardium revealed a reduction in programmed cell death by NAC-enhanced contrast medium that may explain the increase in ischemia tolerance. Last, NAC-enhanced contrast medium administration blunted the rise in serum creatinine levels by about 60% and protected from renotubular apotosis. CONCLUSIONS:NAC-enhanced contrast medium reduces MI size and protects renal function in a pig model of ischemia and reperfusion.
Authors: J M de Bakker; F J van Capelle; M J Janse; A A Wilde; R Coronel; A E Becker; K P Dingemans; N M van Hemel; R N Hauer Journal: Circulation Date: 1988-03 Impact factor: 29.690
Authors: J S Scharfstein; J F Keaney; A Slivka; G N Welch; J A Vita; J S Stamler; J Loscalzo Journal: J Clin Invest Date: 1994-10 Impact factor: 14.808
Authors: Roxana Mehran; Eve D Aymong; Eugenia Nikolsky; Zoran Lasic; Ioannis Iakovou; Martin Fahy; Gary S Mintz; Alexandra J Lansky; Jeffrey W Moses; Gregg W Stone; Martin B Leon; George Dangas Journal: J Am Coll Cardiol Date: 2004-10-06 Impact factor: 24.094
Authors: Luciano F Drager; Lúcia Andrade; João Felipe Barros de Toledo; Francisco R M Laurindo; Luiz Antônio Machado César; Antonio Carlos Seguro Journal: Nephrol Dial Transplant Date: 2004-05-05 Impact factor: 5.992
Authors: Markus Meyer; Stephen P Bell; Zengyi Chen; Iwan Nyotowidjojo; Richard R Lachapelle; Timothy F Christian; Pamela C Gibson; Friederike F Keating; Harold L Dauerman; Martin M LeWinter Journal: J Thromb Thrombolysis Date: 2013-11 Impact factor: 2.300